PR
PRQR.US ProQR Therapeutics BV
- Market cap
- USD 171M
- P/E
- -
- P/B
- 2.26x
- ROE
- -68.3%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is PRQR.US undervalued?
Graham numberThe Graham number of ProQR Therapeutics BV cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
ProQR Therapeutics BV fundamental analysis
No fundamental analysis for ProQR Therapeutics BV yet.
ProQR Therapeutics BV stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About ProQR Therapeutics BV
ProQR Therapeutics N.V., a clinical-stage biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company develops an RNA editing platform through its Axiomer RNA editing technology for genetic disorders with unmet needs. Its lead product candidate, AX-0810, targets na-taurocholate cotransporting polypeptide (NTCP) for the treatment of cholestatic diseases. The company also develops AX-2402, which targets methyl CpG binding protein…
Full company profileProQR Therapeutics BV financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
ProQR Therapeutics BV annual financial statements (EUR; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 2.28M | -1.53M | 4.94M | 1.93M | 1.03M | 1.34M | 3.59M | 6.51M | 18.9M | 15.3M | 21.5M |
| Gross Profit | 1.00M | -2.53M | 3.96M | -115M | 1.03M | 1.34M | 3.59M | 6.51M | 18.9M | 12.7M | 19.6M |
| Operating Income | -39.6M | -40.5M | -36.3M | -57.4M | -42.4M | -57.2M | -65.2M | -31.9M | -30.5M | -42.2M | -48.0M |
| EBITDA | -36.0M | 1.07M | -35.3M | -170M | -48.4M | -54.9M | -56.5M | -24.1M | -24.1M | -36.9M | -44.7M |
| Net Income | -39.1M | -43.6M | -36.9M | -56.7M | -46.6M | -60.7M | -64.4M | -28.1M | -27.8M | -40.5M | -46.6M |
| EPS | -1.67 | -1.72 | -1.08 | -1.38 | -0.93 | -0.95 | -0.90 | -0.35 | -0.34 | -0.38 | -0.33 |
| Balance Sheet | |||||||||||
| Total Assets | 69.1M | 63.8M | 110M | 132M | 121M | 238M | 183M | 152M | 174M | 132M | 119M |
| Total Liabilities | 13.1M | 16.5M | 17.5M | 26.6M | 51.6M | 110M | 112M | 107M | 82.2M | 74.4M | 50.9M |
| Shareholders' Equity | 56.0M | 47.3M | 92.7M | 106M | 69.9M | 129M | 71.6M | 45.7M | 91.7M | 58.0M | 68.2M |
| Cash & Short-term Investments | 62.4M | 57.8M | 106M | 126M | 92.8M | 213M | 101M | 131M | 155M | 109M | 103M |
| Total Debt | 4.85M | 8.70M | 28.1M | 15.2M | 41.9M | 68.7M | 23.4M | 21.8M | 16.1M | 16.4M | 14.6M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -34.2M | -35.0M | -30.7M | -44.0M | -47.1M | -26.0M | -68.5M | 21.5M | -36.4M | -52.8M | -49.5M |
| Capital Expenditure | 2.54M | 121K | 312K | 580K | 924K | 484K | 708K | 1.37M | 1.42M | 1.02M | 1.08M |
| Free Cash Flow | -36.8M | -35.1M | -31.0M | -44.6M | -48.0M | -26.5M | -69.2M | 20.2M | -37.8M | -53.8M | -50.6M |
| Ratios | |||||||||||
| ROE | -69.8% | -92.3% | -39.8% | -53.6% | -66.7% | -46.9% | -90.0% | -61.5% | -30.3% | -69.9% | -68.3% |
| ROA | -56.6% | -68.4% | -33.5% | -43.0% | -38.5% | -25.5% | -35.2% | -18.5% | -16.0% | -30.6% | -39.1% |
| Net Profit Margin | -1,713.5% | - | -746.7% | -2,935.6% | -4,525.3% | -4,549.8% | -1,792.5% | -431.7% | -146.9% | -265.2% | -216.6% |
| Debt to Equity | 0.09x | 0.18x | 0.30x | 0.14x | 0.60x | 0.53x | 0.33x | 0.48x | 0.18x | 0.28x | 0.21x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
ProQR Therapeutics BV dividends
ProQR Therapeutics BV has not paid dividends in the last 9 fiscal years.
Who owns ProQR Therapeutics BV
- Insiders 17.46%
- Institutions 55.27%
- Public & others 27.27%
- Shares outstanding 141M
- Free float 91.4M
Top funds holding PRQR.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| abrdn World Healthcare | 6.68M | 4.73% | +5.98% | Sep 2026 |
| abrdn Life Sciences Investors | 2.98M | 2.11% | 0.00% | Oct 2026 |
| Beleggingsfonds Hoofbosch | 800K | 0.57% | 0.00% | Jul 2026 |
| Nomura Healthcare Fund Class I | 620K | 0.44% | 0.00% | Sep 2026 |
| Fidelity Nasdaq Composite Index | 23.9K | 0.02% | -66.62% | Aug 2026 |
| China Universal Gbl YLBJ QDII CNH | 12.5K | 0.01% | 0.00% | Jun 2026 |
| Knights of Columbus U.S. All Cap Idx I | 607.00 | 0.00% | +49.88% | Sep 2026 |
Top institutions holding PRQR.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Aberdeen Group PLC | 9.67M | 6.84% | +8.23% | Sep 2026 |
| Adage Capital Partners Gp LLC | 9.02M | 6.38% | +44.17% | Jun 2026 |
| Affinity Asset Advisors, LLC | 5.54M | 3.92% | +125.89% | Jun 2026 |
| Privium Fund Management B.V. | 5.52M | 3.91% | +0.97% | Jun 2026 |
| Ikarian Capital, LLC | 3.43M | 2.42% | +129.58% | Jun 2026 |
| Woodline Partners LP | 3.28M | 2.32% | 0.00% | Jun 2026 |
| Heights Capital Management Inc | 2.76M | 1.95% | 0.00% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 1.77M | 1.25% | +35.96% | Jun 2026 |
| Sphera Funds Management Ltd. | 1.76M | 1.24% | 0.00% | Jun 2026 |
| Kynam Capital Management, LP | 1.57M | 1.11% | 0.00% | Jun 2026 |
| Dafna Capital Management LLC | 1.53M | 1.08% | -2.37% | Jun 2026 |
| Squadron Capital Management LLC | 1.51M | 1.07% | 0.00% | Jun 2026 |
| Citadel Advisors Llc | 1.18M | 0.84% | +68.39% | Jun 2026 |
| Two Sigma Investments LLC | 1.14M | 0.81% | +23.93% | Jun 2026 |
| Eversept Partners, LP | 1.02M | 0.72% | 0.00% | Jun 2026 |
| BOOTHBAY FUND MANAGEMENT, LLC | 949K | 0.67% | +167.04% | Jun 2026 |
| Diadema Partners LP | 926K | 0.66% | +414.22% | Jun 2026 |
| UBS Group AG | 639K | 0.45% | +109.41% | Jun 2026 |
| Delaware Management Holdings Inc | 620K | 0.44% | 0.00% | Jun 2026 |
| M28 Capital Management LP | 600K | 0.42% | 0.00% | Jun 2026 |
ProQR Therapeutics BV company profile
- Company name
- ProQR Therapeutics BV
- Ticker
- PRQR.US
- ISIN
- NL0010872495
- Exchange
- USA Stocks
- Listed since
- Sep 18, 2014
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 186
- Fiscal year end
- December
- Address
- Zernikedreef 9, Leiden, Netherlands, 2333 CK
- Phone
- 31 88 166 7000
- Website
- proqr.com
About ProQR Therapeutics BV
ProQR Therapeutics N.V., a clinical-stage biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company develops an RNA editing platform through its Axiomer RNA editing technology for genetic disorders with unmet needs. Its lead product candidate, AX-0810, targets na-taurocholate cotransporting polypeptide (NTCP) for the treatment of cholestatic diseases. The company also develops AX-2402, which targets methyl CpG binding protein 2 mutations for Rett syndrome; AX-2911, which targets PNPLA3 for metabolic dysfunction-associated steatohepatitis; and AX-1412, which targets the B4GALT1 gene for cardiovascular diseases. It has a research and collaboration agreement with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. The company was incorporated in 2012 and is headquartered in Leiden, the Netherlands.
ProQR Therapeutics BV management
9- Mr. Daniel Anton de BoerFounder, CEO & Executive Director · born 1983
- Dr. Gerard Platenburg Ph.D.Co-Founder, Chief Scientific Officer & Executive Director · born 1964
- Mr. Dennis HomChief Financial Officer · born 1975
- Ms. Sheila SponseleeChief People & Operations Officer · born 1984
- Ms. Sarah Cue KielyVice President of Investor Relations & Corporate Communications
- Dr. Cristina Lopez Lopez M.D., Ph.D.Chief Medical Officer · born 1976
- Mr. Christopher Hart Ph.D.Chief Data & AI Officer
- Dr. Golnar KarimianHead of Hepatology
- Ms. Sandra van der KolkJunior Financial Controller